David Malka, Pascale Cervera, Stéphanie Foulon, Tanja Trarbach, Christelle de la Fouchardière, Eveline Boucher, Laetitia Fartoux, Sandrine Faivre, Jean-Frédéric Blanc, Frédéric Viret, Eric Assenat, Thomas Seufferlein, Thomas Herrmann, Julien Grenier, Pascal Hammel, Matthias Dollinger, Thierry André, Philipp Hahn, Volker Heinemann, Vanessa Rousseau, Michel Ducreux, Jean-Pierre Pignon, Dominique Wendum, Olivier Rosmorduc, Tim F Greten
BACKGROUND: Gemcitabine plus a platinum-based agent (eg, cisplatin or oxaliplatin) is the standard of care for advanced biliary cancers. We investigated the addition of cetuximab to chemotherapy in patients with advanced biliary cancers. METHODS: In this non-comparative, open-label, randomised phase 2 trial, we recruited patients with locally advanced (non-resectable) or metastatic cholangiocarcinoma, gallbladder carcinoma, or ampullary carcinoma and a WHO performance status of 0 or 1 from 18 hospitals across France and Germany...
July 2014: Lancet Oncology